Skip to main content

Vigo is pleased to have supported Elevara Medicines on its successful launch, including a $70m Series A financing to advance its lead programme into Phase 2 clinical trials in rheumatoid arthritis and to expand its pipeline into other chronic inflammatory and women’s health conditions.

Author

Vigo Consulting
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.